Oxford BioDynamics to expand strategic focus beyond biomarker discovery to development and commercialization of laboratory tests

Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch® biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch®

Chromatin signatures of DLBCL subtypes.

Field, et. al.,
Cancer Research

Current Advances in Epigenetics.

Hunter, et., al.,
Clinical and Statistical Consideration in Personalized Medicine

Formation of distinct chromatin conformation signatures epigenetically regulate macrophage activation.

Mukhopadhyay, et. al.,
International Immunopharmacology

Validation of a new Epigenetic-based Prognostic Blood test to predict Prostate Cancer Aggressiveness

Pchejetski, D, et. al.,
Annals of Oncology

Development of novel ALS treatment on the basis of mechanisms of cellular chronological life span control.

Youdell, M., et.al.,
12th Annual Northeast Amyotrophic Lateral Sclerosis Consortium

A blood-based epigenetic test for early detection of nasopharyngeal carcinoma (NPC).

Tan, Y., et. al.,
J Clinical Oncology

A novel epigenetic blood test to monitor minimal residual disease in high-risk neuroblastoma.

Petrie, K., et. al.,
Cancer Research

Breast cancer: development of early non-invasive diagnostics to reduce disease mortality and psychological outcomes.

Jeznach, M., et.al.,